Objective: To analyze the effects of Helicobacter pylori on blood pressure, carotid atherosclerosis, long non-coding RNA (LncRNA) MALAT1, nitric oxide (NO), corticosterone and new cardiovascular and cerebrovascular diseases. Methods: The patients with both hypertension and Helicobacter pylori infection were divided into experimental group and control group. 296 cases each.The control group was treated with antihypertensive and lipid-lowering treatment, and the experimental group was treated with anti-Helicobacter pylori drugs on this basis. Then the changes of blood pressure, blood lipid level, carotid intima thickness and heart rate were compared between the two groups. After 2 years of follow-up, the proportion of new cardiocerebral artery occlusion was observed. Thirty-two 6-week-old male rats were divided into spontaneously hypertensive rats (SHR) group A and group B, Wistar-Kyoto (WKY) rats group C and group D, with 8 rats in each group. Rats in group A and group C were given Helicobacter pylori gavage, and rats in group B and group D were given 0.9% NaCl gavage. After 14 weeks, blood and gastric tissue were taken for detection. Results: (1) Helicobacter pylori affected blood pressure, so that the blood pressure of SHR and WKY rats were significantly increased; the degree of hypertension in SHR was more obvious (P＜0.05). (2)The increase of Helicobacter pylori value affected the levels of LncRNA MALAT1, NO and corticosterone (P＜0.05). (3) The proportion of new heart and cerebral artery insufficiency or even occlusion after the decrease of Helicobacter pylori value was less than that of the control group (P＜0.05). Conclusion: (1)The content of Helicobacter pylori is positively correlated with the increase of blood pressure, LncRNA MALAT1 and corticosterone, and negatively correlated with NO. (2) After the treatment of Helicobacter pylori, it can reduce the degree of blood pressure level and the proportion of coronary cerebral artery occlusion.
XIAO Anhui
,
HUANG Guanhua
. Effects of Helicobacter pylori infection on LncRNA, NO and corticosterone in hypertensive patients and rats[J]. Journal of Baotou Medical College, 2024
, 40(8)
: 44
-48
.
DOI: 10.16833/j.cnki.jbmc.2024.08.009
[1] Alkhalil M. A promising tool to tackle the risk of cerebral vascular disease, the emergence of novel carotid wall imaging[J]. Brain Circ, 2020, 6(2): 81-86.
[2] Sun S, Lulla A, Sioda M, et al. Gut microbiota composition and blood pressure[J]. Hypertension, 2019, 73(5): 998-1006.
[3] Li J, Yang XC, Zhou X, et al. The role and mechanism of intestinal flora in blood pressure regulation and hypertension development[J]. Antioxid Redox Signal, 2021, 34(10): 811-830.
[4] 夏行, 马维红. 幽门螺杆菌感染与原发性高血压关系的研究进展[J]. 内科, 2018, 13(2): 215-217, 246.
[5] 汪飞, 唐婷玉, 刘娟, 等. 肠道菌群多样性变化与阻塞性睡眠呼吸暂停合并高血压发病的关系研究[J]. 浙江医学, 2022, 44(8): 846-850, 903.
[6] Fang YZ, Xie HB, Fan CM. Association of hypertension with helicobacter pylori: a systematic review and meta-analysis[J]. PLoS One, 2022, 17(5): e0268686.
[7] Kountouras J, Papaefthymiou A, Polyzos SA, et al. Impact of helicobacter pylori-related metabolic syndrome parameters on arterial hypertension[J]. Microorganisms, 2021, 9(11): 2351.
[8] 杨丽娟, 郑红英, 陈璟, 等. 老年高血压幽门螺杆菌感染者根治后对血管内皮功能及新发心脑血管疾病的影响[J]. 宁夏医科大学学报, 2018, 40(7): 837-839.
[9] Yan XF, Jin JJ, Su XH, et al. Intestinal flora modulates blood pressure by regulating the synthesis of intestinal-derived corticosterone in high salt-induced hypertension[J]. Circ Res, 2020, 126(7): 839-853.
[10] Xue YZ, Li ZJ, Liu WT, et al. Down-regulation of lncRNA MALAT1 alleviates vascular lesion and vascular remodeling of rats with hypertension[J]. Aging, 2019, 11(14): 5192-5205.
[11] Dong ZC, Wu MM, Zhang YL, et al. The vascular endothelial growth factor trap aflibercept induces vascular dysfunction and hypertension via attenuation of eNOS/NO signaling in mice[J]. Acta Pharmacol Sin, 2021, 42(9): 1437-1448.
[12] 郭丽坤, 岑戎. 小檗碱对幽门螺杆菌感染大鼠胃黏膜IFN-γ、TNF-α、IL-2表达的影响[J]. 上海中医药杂志, 2020, 54(S1): 159-161, 166.
[13] De Korwin JD. Helicobacter pylori: quand rechercher une infection et la traiter chez l’adulte?[J]. La Rev De Médecine Interne, 2021, 42(7): 482-491.
[14] 刘敏科, 金华. 肠道菌群与高血压及其危险因素研究进展及问题探讨[J]. 中国微生态学杂志, 2023, 35(2): 245-249.
[15] Soundharrajan I, Kuppusamy P, Srisesharam S, et al. Positive metabolic effects of selected probiotic bacteria on diet-induced obesity in mice are associated with improvement of dysbiotic gut microbiota[J]. FASEB J, 2020, 34(9): 12289-12307.
[16] Lewis-Mikhael AM, Davoodvandi A, Jafarnejad S. Effect of Lactobacillusplantarum containing probiotics on blood pressure: a systematic review and meta-analysis[J]. Pharmacol Res, 2020, 153: 104663.
[17] Berenyiova A, Balis P, Kluknavsky M, et al. Age- and hypertension-related changes in NOS/NO/sGC-derived vasoactive control of rat thoracic aortae[J]. Oxid Med Cell Longev, 2022, 2022: 7742509.
[18] 周毅, 王雪笠, 黎炳护, 等. 辣椒素对AngⅡ诱导VSMC增殖迁移及DOCA-盐引起的高血压大鼠血管重构的影响[J]. 解放军医药杂志, 2022, 34(1): 7-13.
[19] 梅小琴, 陈耀光. LncRNA-Ang362在妊娠期高血压中表达水平及调控PTEN/AKT/mTOR通路对血管平滑肌细胞增殖和迁移的影响[J]. 热带医学杂志, 2023, 23(7): 925-931.
